



UNITED STATES PATENT AND TRADEMARK OFFICE

JO
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/595,029	06/09/2006	Gabriela Chiosis	MSK.P-072	1546
52334	7590	07/20/2007	EXAMINER	
Marina Larson & Associates LLC			KOSSON, ROSANNE	
re: MSK			ART UNIT	PAPER NUMBER
P. O. BOX 4928			1652	
DILLON, CO 80435-4928				
MAIL DATE		DELIVERY MODE		
07/20/2007		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/595,029	CHIOSIS ET AL.	
	Examiner Rosanne Kosson	Art Unit 1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 09 June 2006.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-36 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-36 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____	6) <input type="checkbox"/> Other: _____

DETAILED ACTION***Election/Restrictions***

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-17 and 32-36, drawn to a method of identifying an inhibitor of an Hsp90 protein, comprising performing two assays. In the first assay, the degree of light polarization of an Hsp90 bound to a fluorescently labeled molecule is measured, the degree of light polarization of a mixture of a potential inhibitor, an Hsp90 and a fluorescently labeled molecule is measured, and the difference is calculated. In the second assay, test cells are contacted with the potential inhibitor, and the degree to which the inhibitor inhibits an Hsp90 activity is measured.

Group II, claim(s) 18-23, drawn to a method of identifying an inhibitor of an Hsp90 protein comprising performing two assays. In the first assay, a type of test cells are contacted with the potential inhibitor, and the degree to which the inhibitor inhibits an Hsp90 activity is measured. In the second assay, at least two different types of test cells are contacted with the potential inhibitor, and the degree to which the inhibitor inhibits an Hsp90 activity is measured.

Group III, claim(s) 24-31, drawn to a composition comprising a compound that binds to an Hsp90 and a fluorescent moiety.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons.

The requirement of unity of invention is not fulfilled because there is no technical relationship among these inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" means those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art. Therefore, a technical relationship is lacking among the claimed inventions involving one or more special technical features. The technical feature that links the 3 groups of inventions is a compound that binds to or inhibits an Hsp90.

The inventions of Groups I-III do not share the common special technical feature of a molecule that binds to or inhibits an Hsp90, because Segnitz et al. ("The function of steroid hormone receptors is inhibited by the Hsp90-specific compound geldanamycin," J Biol Chem 272: 18694-

Art Unit: 1652

18701, 1997) disclose the compound geldanamycin, a compound that binds to and inhibits the activity of Hsp90 (see p. 18694 and p. 18699, right col.).

Thus, the technical feature of a compound that binds to or inhibits an Hsp90 does not define the invention over the prior art. Because the common technical feature is not novel (special) with respect to the cited reference, it is clear that the claims of Groups I-III lack a single common technical feature that defines them over the prior art.

Further, an international application containing claims to different categories of inventions will be considered to have unity of invention if the claims are drawn only to one of certain combinations of categories:

- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process (see 37 CFR 1.475(b)-(d)). In the instant case, the claims are drawn to one product and multiple processes, only a particular combination of which including Group I may be considered for unity of invention, i.e., Group I and Group III, (the first named process of using the product and the first named product). Other groups are drawn to an additional process, and other combinations do not comply with the aforementioned Rules. But, because a corresponding special technical feature is not present, Groups I and III cannot be considered to have unity of invention.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows.

- a) If Applicants elect Group I or II, in claim 5 or claim 20, Applicants must elect one of the cancer cell types listed.
- b) If Applicants elect Group I, Applicants must elect either claim 7 or claim 8. Whichever claim is elected, Applicants must elect at least two cell types from that claim as the different cell types. In order to have claim 7 or claim 8 examined, one of the two cell types must correspond to the type of cell elected in claim 5. For example, if breast cancer cells are elected in claim 5, SKBr3 and MCF7 cells may be elected in claim 8.

Art Unit: 1652

c) If Applicants elect Group II, Applicants must elect either claim 22 or claim 23.

Whichever claim is elected, Applicants must elect at least two cell types from that claim as the different cell types. In order to have claim 22 or claim 23 examined, one of the two cell types must correspond to the type of cell elected in claim 20. For example, if breast cancer cells are elected in claim 20, SKBr3 and MCF7 cells may be elected in claim 23.

d) If Applicants elect Group III, Applicants must elect the fluorescent moiety of either claim 25 or claim 27.

Applicants are required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added.

An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: 5, 6, 20, 21 and 24.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons. Claims 5, 7, 8, 20, 22 and 23 recite groups of different cell types, each cell type having different properties and different pathologies. Claims 25 and 27 recite different fluorescent dyes, each of which has a different structure and different chemical properties. Because the claimed species are not art-recognized equivalents, a holding of lack of unity of invention is proper.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04.

Art Unit: 1652

Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rosanne Kosson whose telephone number is 571-272-2923. The examiner can normally be reached on Monday-Friday, 8:30-6:00, alternate Mondays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone

Art Unit: 1652

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Rosanne Kosson
Examiner, Art Unit 1652

rk/2007-07-16

Rosanne Kosson

Ponnathapu Achuta Murthy
PONNATHAPU ACHUTA MURTHY
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 2000
USPTO - 1100
RICHARD V. BURTON BUILDING
1000 DIAZONIA DR., SUITE 200
ALEXANDRIA, VA 22314-1100
(703) 305-3000
(703) 305-3000 FAX